Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Zhejiang Cuize Pharmaceutical Technology Co. Ltd. is currently navigating 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution activity involves 1 distinct examiner and is situated within 1 distinct art unit. Such a focused profile suggests that the company's current engagement with the patent office is limited to a single, specific pharmaceutical or biotechnological inquiry. The concentration in one art unit implies a narrow technical scope for the pending matter, which may simplify the search for relevant prior art.
The examiner MACH, ANDRE is the busiest examiner for the portfolio, holding 1 pending office action. Since the busiest examiner pending count is 1, MACH, ANDRE is the sole official currently reviewing the company's active applications. Practitioners managing this portfolio must tailor their responses to the specific standards of the assigned examiner. The lack of multiple pending actions or examiners means that the immediate success of the company's prosecution efforts relies entirely on the resolution of this single matter. Consequently, the practitioner must focus on the specific procedural requirements of the assigned examiner and the technical precedents of the 1 distinct art unit involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MACH, ANDRE | 1 | 44.9% | +51.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18554118 | ROPIVACAINE SUSPENSION INJECTION, AND PREPARATION METHOD THEREFOR | MACH, ANDRE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18554118 | ROPIVACAINE SUSPENSION INJECTION, AND PREPARATION METHOD THEREFOR | MACH, ANDRE | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18554118 | ROPIVACAINE SUSPENSION INJECTION, AND PREPARATION METHOD THEREFOR | MACH, ANDRE | 1615 | §103§112 | Non-Final OA | — | Pending | Oct 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial